



HALF YEARLY RESULTS 2014

STAR CONFERENCE October 2nd, 3rd, 2014

Company Presentation



Disclaimer

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.







- 2. THE GLOBAL LASER MARKET
- 3. EL.EN. GROUP
- 4. H1 2014 FINANCIAL RESULTS
- 5. 2014 GUIDANCE
- 6. EL.EN. STOCK, MULTIPLES & COMPARABLES





Lasers and Laser Applications





LASER

Light Amplification Stimulated by Emission of Radiation

MEDICAL LASER Systems





INDUSTRIAL LASER Systems



MEDICAL applications





Laser-Assisted LiposuctionCourtesy of: G. Addamo, Gynaecologist and A. Gaspar,
Gynaecologist - Argentina.





Nd:YAG Laser Courtesy of: P. Campolmi, MD - G. Cannarozzo, MD - P. Bonan, MD. Florence, Italy.





Combined treatment of scars with DOT + RF. *Courtesy of: N. Zerbinati, MD. Varese – Italy.*






DOT Therapy.Courtesy of: P. Campolmi, MD - G. Cannarozzo, MD - P. Bonan, MD. Florence — Italy.



MEDICAL applications











FT Pulsed Light Handpiece Courtesy of M. Patarin, MD - Challans, France.






Dermatosis papulosa Nigra.Courtesy of: P. Campolmi, MD - G. Cannarozzo, MD - P. Bonan, MD. Florence — Italy.




INDUSTRIAL applications










CONSERVATION and restoration

Pompei – Villa dei Misteri





"Essays cleaning of the frescoes of the Villa dei Misteri in Pompei" June 2013, courtesy of Superintendence for Archaeological Heritage of Naples and Pompei



The Global Laser Market








The MEDICAL Laser Market

| Market CAGR 2013-2018 | | | | | | | | | |
|-----------------------|---------|--------|-------|---------|-------|--|--|--|--|
| Market segment | North | Europe | Asia | Latin | Total | | | | |
| | America | | | America | | | | | |
| • | | | | | | | | | |
| Energy Devices | 6,9% | 3,2% | 15,3% | 9,0% | 7,8% | | | | |
| Skin Rejuvenation | 7,3% | 5,8% | 13,0% | 11,8% | 8,2% | | | | |
| Body Contouring | 11,3% | 6,4% | 18,3% | 15,7% | 12,4% | | | | |

Source: Medical Insight, Inc.



The INDUSTRIAL Laser Market



Source: Optech Consulting

The INDUSTRIAL Laser Market

Global market and forecast for high power laser systems by application (by value)

| By Value | Global Ma | arket (EUR Million | n) | CAGR (%) | | |
|------------------------------|-----------|--------------------|-------|-----------|-----------|--|
| | 2013 | 2016 | 2020 | 2013-2016 | 2016-2020 | |
| Cutting | 2.408 | 3.014 | 3.965 | 7,8 | | |
| Welding and Brazing | 1.249 | 1.605 | 2.231 | 8,7 | 8,6 | |
| Surface treatment oand Other | 50 | 63 | 86 | 8,3 | 8,1 | |
| Total | 3.707 | 4.682 | 6.282 | 8,1 | 7,6 | |



Source: Optech Consulting



El.En. Group







Group Overview

High –Tech laser photonics Group

Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications

Know-how based on 30 years stratification of multidisciplinary experience


June, 30th 2014: Consolidated Revenues of €80 mln, up 9% YoY, 931 employees

Global positioning



El.En. Group

El.En. group in the world



Strategic Strengths

Multidisciplinary and multifacility R&D activity: sources, systems, applications

Covering Medical and Industrial laser markets

Raising technological entry barriers through R&D

Industrial


✓ Combine High tech laser source development with flexible production facilities in high growth areas

Medical

- ✓ Maximize market penetration by multi brand approach
- ✓ Open new market segments by developing innovative applications
- ✓ Leverage worldwide distribution




Consolidated Revenues and EBIT





Cynosure: the investment history



Residual shares 1 mln Current price \$ 23



R&D Activity

Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser- tissue interaction

Raising Technological / Clinical entry barriers

Central role of PHOTOBIOLAB

Medical Aesthetic new multi-application platforms

Vascular lesions systems: VASQ (Dye), Yellow Star Pro

Clinical studies on Mona Lisa Touch

Clinical studies on cutaneous ulcers

Laser beam delivery and focusing head for metal cutting

Patents development



Medical/Aesthetic

Aesthetic

Hair Removal

Vascular Lesions

Skin Rejuvenation

Pigmented Lesions

Treatment of Cellulite

Acne

Tattoo Removal

Anti - Aging

LaserBody Sculpting

Removal of Unwanted Fat













Medical

Gynaechology

Endovascular

Dermatology

Psoriasis and Vitiligo

Dentistry

Therapy

General Surgery

Urology

ENT





H1 2014 Financial Results







Consolidated P&L

| Euro/000 | 30/06/13 | | 30/06/14 | | Var.% |
|--------------------------|----------|--------|----------|--------|--------|
| Revenues | 73.837 | 100,0% | 80.398 | 100,0% | 8,9% |
| Gross margin | 36.343 | 49,2% | 38.058 | 47,3% | 4,7% |
| EBITDA | 5.940 | 8,0% | 7.044 | 8,8% | 18,6% |
| EBIT (*) | 3.733 | 5,1% | 6.484 | 8,1% | 73,7% |
| Income before taxes (**) | 3.387 | 4,6% | 11.359 | 14,1% | 235,4% |
| Net income | 1.257 | 1,7% | 8.492 | 10,6% | 575,4% |
| Net Income per share | 0,26 | | 1,77 | | 575,4% |

(*) 2014 Non recurring: + 1,5 mln of euro

(**) 2014 Total one time and non recurring: + 6,0 mln of euro




Consolidated BS

| Euro/000 | 31/12/13 | 30/06/14 | Var.% |
|--------------------------|----------|----------|-------|
| Total non current assets | 72.976 | 48.436 | -34% |
| Net working capital | 48.414 | 52.609 | 9% |
| Net financial position | 21.820 | 40.087 | 84% |
| Long term liabilities | 8.904 | 6.807 | -24% |
| Net Equity | 134.306 | 134.325 | 0% |
| Net capital employed | 112.486 | 94.238 | -16% |



El.En. – Revenues breakdown by business

21.648



Surgical

Dental Service

Physiotherapy



+16%


June 30th, 2013 June 3


June 30th, 2014

25.139

2014: +9%










2014 Guidance







2014 forecast



EBIT improvement on 2013

Palomar settlement (EBIT + 1,5 mln)

Gain on sale of Cynosure shares (Net Income +4,5 mln)






El.En. Stock, Multiples & Comparables







El.En. stock





El.En. multiples

Stockholder's Equity per share * 27

Price / Book Value Adj. 0,83

EV /EBIT (85% EBIT) 4,58

EV / Sales (85% Sales) 0,37

El.En. Market Cap. 108,5 @ €22,5

Net financial position 40,1 @ 30/06/14

Market value of 1,0 mm Cynosure shares 18,0 @ \$23,19 (Euro/Usd=1,2851)

Enterprise Value 50

Stockholder's Equity net of minorities, 130,6

* (with Cynosure shares at market value)



El.En. Comparables

| Medical/Aesthetic | Price | Revenue | Var.% Revenue | EBIT | EBIT% | МК.Сар. | EV | EV/Sales (*) | EV/EBIT (*) | P/Book Value |
|-------------------|---------|-----------|------------------|------------|-------|-------------|-------------|-----------------|----------------|-----------------|
| | Ć10.03 | Ć424 424 | 70/ | ¢(054) | 4.0/ | 6207.420 | ¢244.205 | 4.20 | | 4.70 |
| Syneron | \$10,83 | \$121.431 | -7% | \$(951) | -1% | \$397.130 | \$311.385 | 1,28 | n.a. | 1,70 |
| Zeltiq | \$25,00 | \$78.036 | 68% | \$(4.446) | -6% | \$938.140 | \$877.091 | 5,62 | n.a. | 24,16 |
| Lumenis | \$8,98 | \$138.295 | 9% | \$6.698 | 5% | \$319.770 | \$276.239 | 1,00 | 20,62 | 3,69 |
| Cutera | \$10,44 | \$33.913 | -5% | \$(6.488) | -19% | \$149.430 | \$67.832 | 1,00 | n.a. | 1,41 |
| Biolase | \$2,69 | \$21.704 | -25% | \$(10.827) | -50% | \$118.050 | \$119.271 | 2,75 | n.a. | 40,66 |
| Cynosure | \$23,19 | \$134.577 | 48% | \$7.744 | 6% | \$501.910 | \$415.072 | 1,54 | 26,80 | 1,48 |
| Industrial | | | | | | | | | | |
| IPG Photonics Co. | \$69,10 | \$362.779 | 17% | \$126.538 | 35% | \$3.600.000 | \$3.119.292 | 4,30 | 12,33 | 3,52 |
| Rofin-Sinar | \$23,64 | \$262.878 | -15% | \$15.109 | 6% | \$662.130 | \$517.477 | 0,98 | 17,12 | 1,19 |
| Prima Industrie | €15,70 | €154.210 | -5% | €9.291 | 6% | €156.052 | €258.261 | 0,84 | 13,90 | 1,41 |
| I | | | | | | | | | | |
| El.En. (1) | €22,50 | €80.398 | 9% | €6.484 | 8% | €108.548 | €50.441 | 0,37 | 4,58 | 0,83 |





El.En. SPA

Enrico ROMAGNOLI

Investor Relations Manager
tel. +39 055-8826807

E-mail: finance@elen.it

POLYTEMS HIR SRL

Bianca FERSINI MASTELLONI

Financial Communication

Tel. +39 06-6797849 / +39 06-69923324

E-mail: b.fersini@polytemshir.it

POLYTEMS HIR SRL

Veronica ADRIANI

Press office

Tel. +39 06-6797849 / +39 06-69923324

E-mail: v.adriani@polytemshir.it